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Abstract
During chemotherapy for childhood acute lymphoblastic leukemia, all organs
can be affected by severe acute side effects, the most common being
opportunistic infections, mucositis, central or peripheral neuropathy (or both),
bone toxicities (including osteonecrosis), thromboembolism, sinusoidal
obstruction syndrome, endocrinopathies (especially steroid-induced adrenal
insufficiency and hyperglycemia), high-dose methotrexate-induced
nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and
hyperlipidemia. Few of the non-infectious acute toxicities are associated with
clinically useful risk factors, and across study groups there has been wide
diversity in toxicity definitions, capture strategies, and reporting, thus
hampering meaningful comparisons of toxicity incidences for different leukemia
protocols. Since treatment of acute lymphoblastic leukemia now yields 5-year
overall survival rates above 90%, there is a need for strategies for assessing
the burden of toxicities in the overall evaluation of anti-leukemic therapy
programs.
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Introduction
The best contemporary chemotherapy for childhood acute 
lymphoblastic leukemia (ALL) now yields 5-year overall survival 
(OS) rates above 90%, which reflects intensified chemotherapy 
with treatment stratification directed by the somatic mutations 
and early response to chemotherapy, better use of conventional 
anti-leukemic agents, and improved supportive care, including 
broad-spectrum antibiotics to combat opportunistic infections1,2. 
However, a significant proportion of leukemic deaths, not least 
for lower-risk patients, are caused by therapy rather than by the 
leukemia itself, and this is just the tip of the toxicity iceberg3. 
Nearly all patients encounter mucositis and serious, though man-
ageable, infections, and although various other severe, acute 
toxicities individually have relatively low incidences, almost 
50% of all patients will be affected by at least one of these4. 
Whereas recent high-throughput, cost-effective technologies have 
revolutionized our insight into the somatic mutational landscape 
of ALL, disease pathogenesis, and drug resistance mechanisms5, 
our understanding of non-infectious chemotherapy-associated 
acute toxicities remains limited, including how to prevent and treat 
them. This reflects their rarity (calling for international collabo-
ration), diverse definitions and capture strategies across study 
groups, lack of tissue specimens to map pathogenesis, and 
uncertain associations with common germline DNA variants6,7. 
This review summarizes recent advancements in the exploration 
of non-infectious, chemotherapy-associated acute toxicities and 
outlines strategies for future research.
The toxicity scenario
Every organ can be affected by acute side effects of anti- 
leukemic chemotherapy, the most common being opportunistic 
infections, mucositis, central or peripheral neuropathy (or both), 
bone toxicities (including osteonecrosis, ON), thromboembo-
lism (TE), sinusoidal obstruction syndrome (SOS), endocrinopa-
thies (especially corticosteroid-induced adrenal insufficiency and 
hyperglycemia), high-dose methotrexate (HD-MTX)-induced 
nephrotoxicity, asparaginase-associated hypersensitivity, pancrea-
titis, and hyperlipidemia. Other toxicities, including myopathy 
and some rare inflammatory toxicities (for example, epidermoly-
sis), will not be addressed in this review.
Few of the non-infectious acute toxicities are associated with 
clinically useful risk factors, and comparison of their frequency 
across various anti-leukemic treatment programs has been ham-
pered by wide diversities in toxicity definitions, capture strate-
gies, and reporting, thus hampering meaningful comparisons 
of toxicity incidences. The toxicities have traditionally been 
defined and graded according to the US National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTCAE)8. 
However, these are generic in their grading and frequently inap-
propriate for children9 and for the acute toxicities seen during 
childhood ALL therapy. Accordingly, 15 international childhood 
ALL study groups (Ponte di Legno Toxicity Working Group, 
or PTWG) have developed consensus definitions for 14 acute 
toxicities7.
Mucositis
Mucositis is a debilitating adverse effect that is reported to occur 
in at least 40% of patients after high-dose anti-metabolites or 
DNA-damaging drugs, including high-dose alkylating agents 
given as part of conditioning therapy prior to hematopoietic stem 
cell transplantation (hSCT)10–13.
Risk factors for mucositis include low body weight, reduced 
renal function, low neutrophil counts, and elevated pre- 
therapeutic levels of inflammatory mediators10,12,14,15. In addition, 
the risk of severe mucositis has, albeit with conflicting results, 
been associated with common DNA polymorphisms, including 
the folate pathway methylenetetrahydrofolate reductase (MTHFR, 
particularly C677T)16 and DNA repair17.
Oral mucositis ranges from soreness with erythema and edema to 
painful, ulcerative mucositis requiring narcotic analgesics, which 
may lead to poor nutritional status18. Intestinal mucositis typically 
develops in parallel with abdominal pain, diarrhea or constipation, 
nausea, and vomiting, but oral and intestinal mucositis may not 
coincide18. They both tend to peak at the time of neutrophil nadir 
10 to 14 days after chemotherapy and typically resolve during the 
subsequent 5 to 10 days.
Gastrointestinal mucositis reflects release of damage-associated 
molecular patterns that are sensed by pattern recognition recep-
tors such as Toll like-receptors, causing release of inflammatory 
cytokines propagating an inflammatory response19–21. This is fol-
lowed by an ulceration phase and finally resolution19. The normal 
intestinal microbiome may play a protective role by stimulating 
endothelial cell proliferation and mucous production, and intesti-
nal dysbiosis due to chemotherapy and antibiotics could aggravate 
mucositis, but this awaits clinical validation21–23. Severe mucositis 
disrupts the intestinal immunological barrier and is a risk factor for 
systemic infections, although it has been most intensively studied 
in the hSCT setting22,24. Accordingly, intestinal mucositis defined 
by hypocitrullinemia reflecting a reduced population of functional 
enterocytes may be better than neutropenia at defining the risk 
period for bacteremia24.
Although several studies have demonstrated temporal associa-
tions between gastrointestinal toxicity, systemic inflammation, and 
fever, infections can be proven in only less than 50% of febrile 
neutropenic episodes25,26, and the cause in microbiologically nega-
tive cases is more likely systemic inflammation—for example, 
C-reactive protein, interleukin-6, and in vitro cytokine produc-
tion—than opportunistic microorganisms13,27–29. This has led to the 
introduction of febrile mucositis as a complementary term to the 
ubiquitous febrile neutropenia28. hSCT studies have linked systemic 
inflammation to adverse outcome and increased treatment-related 
mortality30,31. It is conceivable, but not yet shown, that this also 
holds true for ALL.
Numerous interventions have been tested for the prevention or 
amelioration of mucositis as reviewed and regularly updated by 
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the Mucositis Study Group of the Multinational Association of 
Supportive Care in Cancer and International Society of Oral 
Oncology32. Parenteral non-steroid anti-inflammatory drugs, anti-
epileptics, neuroleptics, and opioids are still the mainstay of pain 
control, despite often being insufficiently effective33. Probiotics 
containing lactobacillus species seem to reduce chemotherapy-
induced diarrhea and mucositis but have been tested only in highly 
specific treatment settings and await formal testing in patients with 
chemotherapy-induced neutropenia and mucosa barrier dysfun-
tion34–37 (NCT02544685). Other less established interventions of 
some efficacy include intravenous glutamine, cryotherapy, recom-
binant keratinocyte growth factor-1, and low-level laser therapy 
for oral mucositis32. However, most of these approaches have been 
studied only insufficiently (if at all) during ALL chemotherapy.
Central neurotoxicity
Central nervous system (CNS) toxicities during treatment occur 
in 10% to 15% of patients with childhood ALL and cover a wide 
spectrum of syndromes with overlapping symptoms, including 
seizures38, HD-MTX-related stroke-like syndrome (MTX-SLS)39 
with or without reduced consciousness, posterior reversible 
encephalopathy syndrome (PRES)40, and steroid psychosis41,42, 
and these may result in permanent or progressive neurocognitive 
defects (for example, attention, executive function)43–45 with or 
without white matter changes on magnetic resonance imaging 
(MRI).
Corticosteroids frequently cause transient changes in sleep 
pattern, mood, and cognition, and this can be quite burdensome to 
both patients and parents46. Corticosteroids may affect the neuro-
transmitters dopamine or serotonin, deregulate the hypothalamic-
pituitary-adrenal (HPA) axis, and cause hippocampal injury47. 
In general, the risk of acute, severe neurotoxicity cannot be pre-
dicted, but the risk is higher for children below six years and for 
treatment with dexamethasone compared with prednisolone, 
potentially reflecting higher CNS penetration and longer half-life 
in CNS of dexamethasone48–50. Germline DNA polymorphisms in 
genes related to drug disposition or neurogenesis or both have been 
associated with neurotoxicity51, but these candidate gene associa-
tions remain to be validated.
Seizures occur in approximately 10% of children with ALL38. 
They can occur both as an isolated symptom, together with vari-
ous other CNS toxicities (for example, intracranial hemorrhage 
or thrombosis, PRES, or MTX-SLS), or second to electrolyte and 
metabolic disturbances or to infections. Many patients subsequently 
require long-term anti-convulsive therapy, female sex being a 
significant risk factor52.
MTX-SLS, which is characterized by focal neurological deficits 
or hemiparesis and often accompanied by disturbances in speech, 
affect, or consciousness (or a combination of these), develops 
within two to three weeks (usually 2 to 14 days) after HD-MTX 
or intrathecal MTX administration and waxes and wanes over the 
subsequent hours to days and then resolves within a few days39,53. 
MTX interferes with the methionine/homocysteine pathway 
and purine de novo synthesis pathways, disrupts myelin, causes 
accumulation of homocysteine and adenosine, and influences 
neurotransmitter status with a strong excitatory effect on the 
N-methyl-D-aspartate receptor (NMDAR). Vitamin B12 deficiency 
can promote these disturbances54. The incidence of SLS varies from 
less than 1% to 15% in the literature and appears to vary accord-
ing to the scheduling and intensity of MTX and co-administration 
of other agents such as cyclophosphamide and Ara-C and appears 
more frequently in children older than 10 years39. Most patients 
make a full recovery, although there are reports of persisting 
neurological deficits, and the risk of recurrence with subsequent 
MTX therapy is low39. Dextromethorphan, a non-competitive 
antagonist to NMDAR, or aminophylline (more relevant for acute 
MTX-induced neurotoxicity) has been advocated on the basis of 
small series55,56. The effect may be dramatic, but the use of these 
interventions awaits formalized validation. MRI will not always 
be able to confirm MTX-SLS but often reveals characteristic 
changes allowing discrimination of MTX-SLS from PRES57.
PRES is a clinico-radiological entity frequently seen dur-
ing the first months of ALL therapy, reflecting disturbances of 
cerebrovascular autoregulation and inconsistently character-
ized by headache, altered mental status, seizures, and visual 
disturbances40,58,59. It may have several causes, predominantly 
arterial hypertension, chemotherapy, and corticosteroids, but the 
exact cause can frequently not be determined in the individual 
patient58. On cranial MRI, areas of vasogenic edema are pre-
dominant but not restricted to the posterior regions of the brain 
or being exclusively bilateral. Affected areas are hypointense on 
T1-weighted and hyperintense on T2-weighted MRI59. In contrast 
to MTX-SLS, PRES is hyperintense on apparent diffusion- 
weighted coefficient MRI images.
Some patients develop frank psychosis during corticosteroid 
therapy41,42. There are no clear guidelines for their clinical manage-
ment, but sleep medication and tranquilizers and, in severe cases, 
anti-psychotics (for example, risperidone) can be indicated60.
Transverse myelitis is a very rare complication seen in children 
with or without hematological malignancies61. It may occasion-
ally be associated with malignant infiltration62 but can also be seen 
as a result of intensive chemotherapy, and high-dose cytarabine, 
MTX, and vincristine have been suspected to play a role63.
Peripheral neuropathy
Peripheral motor or sensory neuropathy or both are common, 
usually caused by vincristine, and in general completely revers-
ible but may require many months for improvement64,65. In severe 
cases, they are occasionally associated with Charcot-Marie-Tooth 
disease66,67.
Metabolic drug-drug interactions may enhance vincristine 
neurotoxicity68. Vincristine is inactivated by the major drug- 
metabolizing CYP isoform in humans, CYP3A4, and the azoles 
ketoconazole, itraconazole, and posaconazole are potent inhibitors 
of CYP3A469. The potency of the azoles fluconazole and voricona-
zole as CYP3A4 inhibitors are much lower but may be clinically 
significant at high doses. A few germline DNA variants and gene 
expression profiles have been associated with the risk of vincris-
tine-induced neuropathy64,70.
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Bone toxicities
The pathophysiology of osteoporosis during ALL therapy is 
uncertain, but the leukemia itself and the use of corticosteroids 
may cause osteoporosis and fractures, including multifocal 
compression fractures of the spine71–74, and osteoporosis affects 
up to 20% of newly diagnosed children with ALL75. Five-
year cumulative incidence of fractures has been reported to 
be 10% to 15% with no overall incidence difference between 
post-induction prednisolone or dexamethasone, although for 
adolescents dexamethasone seems to be associated with a higher 
risk73,76.
The most severe skeletal complication is symptomatic ON, 
caused by bone death resulting from poor blood supply77. The 
PTWG has published a consensus definition of ON that accounts 
for localization of ON, joint deformation and the impact of ON 
on symptoms and self-care7. If routine MRI is performed, an even 
higher frequency of non-symptomatic ON will be detected78. Thus, 
the overall reported frequency varies from less than 5% to more 
than 70%, and females and adolescents have the highest risk79,80. 
ON is mainly diagnosed during the second year of ALL therapy 
(that is, during maintenance therapy), although presentation can 
occur earlier or even after cessation of therapy78,81. Hips and knees 
are most commonly affected in both subclinical and clinical cases, 
and often multiple joints are involved77,81. Many will suffer from 
daily pain, decreased ability of physical activity (or even need 
of a wheelchair), and reduced quality of life81,82. ON can lead to 
joint articular surface collapse with debilitating arthritis and need 
for joint-preserving or joint replacement surgery during the early 
phase of ON or months or years later.
So far, the only proven preventive measure for ON is giving 
dexamethasone intermittently rather than continuously79. Corti-
costeroids contribute to the development of ON through osseous 
lipocyte hypertrophy with resultant increased pressure within 
the bone, which can cause vascular collapse and necrosis, and 
corticosteroids can cause direct toxicity to osteocytes. Fat emboli, 
vasculitis, or microthromboemboli that cause vascular occlu-
sion can also contribute. Accordingly, hyperlipidemia induced 
by corticosteroids and asparaginase has been suggested to be 
associated with increased risk of ON, although most studies have 
been inconclusive78,83.
Genetic risk factors have been reported in pathways associated 
with the glutamate receptor, bone, lipid and folate metabolism, 
thymidylate synthase, corticosteroid disposition, and adipogenesis, 
but the associations have in general not been validated78,84–86.
The benefits of prognostication of ON by imaging await 
validation87,88. Future research should focus on potential risk 
factors for various grades and for single-versus-multiple site ON, 
on the association with metabolism of drugs that may influence 
lipid profiles and coagulation78, on the long-term outcome of ON, 
on improved guidelines for treatment adaptation and interventive 
surgery, and on the association of germline DNA variants with 
phenotype subsets.
Thromboembolisms
TE located to the venous system is most common, and half of 
the cases involve the CNS89–91. The cumulative incidence of 
symptomatic venous TE is 2 to 8%90–93, but asymptomatic cases 
have been reported in up to 70% of patients92,94. Risk factors for 
TE include the leukemia itself, older age, central line catheters, 
immobilization, infections, systemic inflammation, and therapy 
with asparaginase or corticosteroids or both76,90,93,95,96, whereas 
inherited thrombophilia risk factors, including common germline 
DNA polymorphisms, do not seem to play a role or at best remain 
uncertain96. The fatality rate of venous TE is highest in children 
with thromboses in cerebral veins, and studies on the benefits of 
anti-thrombotic prophylaxis, preferably with the novel oral anti-
coagulants, are needed90,97,98.
Sinosoidal-obstruction syndrome
Until recently, SOS, previously known as veno-occlusive 
disease99, has primarily been a serious complication of hSCT 
and is otherwise rare during childhood ALL therapy except with 
continuous oral thioguanine100, not least in patients who carry 
low-activity alleles for thiopurin methyl transferase101. Doppler 
ultrasound showing reversed hepatic portal flow may aid the 
diagnosis, but a normal flow does not exclude the diagnosis and 
thus is not a mandatory diagnostic requirement. Instead, at least 
three of five criteria need to be fulfilled: that is, hepatomegaly, 
hyperbilirubinemia above upper normal limit (UNL), ascites, 
weight gain at or above 5%, and thrombocytopenia (transfusion-
resistant or otherwise unexplained by treatment or both)7.
The pathogenesis remains unclear, but drug-induced damage 
to hepatic endothelium and microcirculation and subsequent 
ischemic hepatocellular necrosis are the presumed mecha-
nism99,102,103. Previously, SOS occurred extremely rarely during 
6-MP therapy100 but recently has been described as a frequent com-
plication to continuous polyethylene glycol-linked Escherichia 
coli asparaginase preparation (PEG-asparaginase) during 
6-MP-based maintenance therapy when combined with pulses 
of either HD-MTX or vincristine/dexamethasone, probably 
reflecting the impact of asparaginase on 6-MP pharmacokinet-
ics causing higher drug metabolite levels104. Management of SOS 
during thiopurine therapy follows the same principles as manage-
ment of SOS following hSCT: that is, fluid and sodium chloride 
restriction, diuretics, and, in the rare severe cases, defibrotide.
Endocrinopathies
There is a paucity of prospective longitudinal studies determin-
ing endocrine changes during ALL therapy, and the existing 
studies have small sample sizes. Growth retardation and relative 
growth hormone deficiency are common during ALL therapy, 
but usually an adequate growth catch-up is obtained after cessa-
tion of therapy in children who do not receive radiotherapy105,106, 
but with a trend toward reduced final height107.
A significant weight gain is seen in up to 40% of children with 
ALL, primarily reflecting exposure to corticosteroids and 
reduced physical activity with insulin resistance, hyperglycemia, 
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and prediabetes, which could indicate the need for dietary 
modifications and insulin therapy108–111. The risk of corticos-
teroid-induced hyperglycemia is aggravated by asparaginase 
therapy112,113. The prevalence of hyperglycemia during ALL 
therapy has been reported to be 10% to 20% during treatment 
with asparaginase and corticosteroids, most frequently in children 
above 10 years of age, with resolution after cessation or taper-
ing down of these drugs112–116. Medication-induced diabetes may 
be a marker for metabolic disease later in life116. Finally, hyper-
glycemia and obesity both have been associated with reduced 
event-free survival117,118.
Fasting hypoglycemia is common during MTX/thiopurine- 
based maintenance therapy, especially in children below 6 years 
of age, but resolves after discontinuation of therapy119,120. It may 
reflect lowered plasma levels of the gluconeogenic amino acids 
(alanine and glutamine) as well as impaired glycogenolysis or 
glyconeogenesis119,121.
Corticosteroids cause a suppression of the HPA axis with 
secondary adrenal insufficiency and impaired stress response 
in nearly all patients, which for some patients may last several 
months after cessation of corticosteroid therapy irrespective of 
whether prednisolone or dexamethasone has been used122. It may 
be aggravated by co-administration of fluconazole122. Thus, corti-
costeroid replacement is indicated during the first weeks to months 
after cessation of corticosteroid therapy, not least during episodes 
of serious stress unless a stimulation test has shown a normal 
adrenal response122,123. The duration of adrenal insufficiency has 
been ascribed to variants of the GR gene124, but formal genome-
wide association analyses are lacking.
HD-MTX-related nephrotoxicity
Alkalinization and vigorous hydration reduce the risk of significant 
nephrotoxicity with HD-MTX, but approximately 3% of patients 
will experience severe renal toxicity that will further compromise 
MTX clearance125–128. The nephrotoxicity is likely to be related 
to precipitation of MTX crystals in the kidneys and this is partly 
due to insufficient hydration and alkalization129,130. Plasma creati-
nine usually peaks within a few days after initiation of the HD-
MTX infusion and returns to baseline after a few weeks. Nearly 
all patients will subsequently tolerate full-dose HD-MTX with-
out recurrent nephrotoxicity127,128. Higher doses of folinic acid, 
adjusted by the plasma MTX levels, are essential to limit the risk 
of life-threatening myelosuppression and mucositis, but whether 
over-rescue could increase the risk of relapse remains an unsolved 
challenge131–133. In cases with extremely delayed MTX clear-
ance, glucarpidase may be helpful to degrade MTX by enzymatic 
cleavage to 2,4-diamino-N10-methyl-pteroic acid (DAMPA) 
and glutamate127,128, but it does not promote restoration of renal 
function. Proton pump inhibitors and non-steroidal anti-inflam-
matory drugs134–142 as well as foodstuff (for example, licorice143) 
and beverages (with low pH or sweetened with licorice extract) 
have been suspected to affect the MTX clearance144. Since the 
introduction of 5-HT3 receptor antagonists, emesis is not a 
problem during HD-MTX and not linked to acute kidney injury.
Trimethroprim-sulfamethoxazole used as Pneumocystis jiroveci 
prophylaxis during ALL therapy does not seem to interfere with 
HD-MTX PK145.
Several germline DNA variants are associated with MTX clear-
ance, most notably in SLCO1B146–149, but none has yet been 
implemented in HD-MTX dosing strategies or been shown to be 
associated with extremely delayed MTX clearance.
Toxicities secondary to asparaginase therapy
Asparaginase causes a range of toxicities due to asparagine 
depletion and disturbed protein synthesis. These toxicities may 
occur in up to 20 to 25% of all patients4 and may lead to discon-
tinuation of asparaginase therapy, which may increase the risk of 
relapse, not least in the CNS150,151.
Asparaginase-associated allergy
The various asparaginase preparations and recombinant analogs 
differ in their biologic half-lives (shortest for Erwinia chrysan-
themi-derived asparaginase and longest for PEG-asparaginase) 
and in their immunogenicity (lowest for PEG-asparaginase)152,153. 
Asparaginase can induce antibody formation that neutralizes 
asparaginase with or without (so-called silent inactivation) clinical 
signs of hypersensitivity154–156. Identification of silent inactivation 
requires measurement of plasma asparaginase activity levels.
The reported frequency of allergic reactions ranges from 3 to 75% 
depending on the type, dose, route, and duration of asparaginase 
administration, and allergic reaction primarily occurs after the 
first or second dose and virtually always is associated with zero 
asparaginase activity150,154,157–162. The reactions range from mild, 
local reactions to life-threatening systemic responses, including 
urticaria, symptomatic bronchospasm, edema/angioedema, and 
hypotension. Premedication with corticosteroid and anti- 
histamines and increased infusion time can reduce allergic 
symptoms but do not prevent asparaginase inactivation, and thus 
symptoms of hypersensitivity indicate the need to switch from 
E. coli-derived preparations to Erwinia asparaginase (or vice 
versa)7,163. Less immunogenic asparaginase preparations are 
emerging but are not routinely used in first-line therapy164–166.
Allergic-like reactions (for example, vomiting, stomach ache, or 
rash) with intact asparaginase activity can be seen but do not indi-
cate discontinuation of the drug7. Therapeutic drug monitoring can 
be helpful for differentiating allergy and allergic-like reactions154. 
HLA-DRB1*07:01 and genetic variations in GRIA1 have been 
associated with a higher incidence of hypersensitivity and anti-
asparaginase antibodies167,168.
Asparaginase-associated pancreatitis
Asparaginase-associated pancreatitis (AAP) has a reported inci-
dence of 2 to 18% depending on the cumulative asparaginase dose 
(that is, treatment duration) and toxicity capture strategies but 
seemingly not on the route of administration7,158,169–174. AAP is 
most often diagnosed within two weeks of asparaginase exposure 
(median of 11 days with PEG-asparaginase), but the interval may 
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be longer175. The diagnostic criteria defined by the PTWG7 are 
similar to those developed for pancreatitis in general176 and require 
two of three criteria to be met: (i) abdominal symptoms sugges-
tive of AAP, (ii) characteristic findings of pancreatitis on imaging, 
and (iii) serum lipase or amylase or both at least three times the 
UNL, and both enzymes should be measured because of a poor 
correlation between the two175. If imaging shows pancreatic necro-
sis or hemorrhage and/or the abdomimal symptoms and elevated 
pancreatic enzymes at least three times the UNL persist for 
more than 72 hours, AAP is classified as severe and otherwise as 
mild.
Most AAP episodes are accompanied by systemic inflammatory 
responses (fever, elevated heart rate, elevated respiratory rate, or 
hypotension) and thus may easily be misinterpreted as sepsis. In 
addition to transient or permanent discontinuation of asparaginase 
therapy, treatment of AAP includes appropriate triage, fluid resus-
citation, antibiotics (until an infection is ruled out), and monitoring 
for and treatment of AAP-related complications177. The mortality 
rate is low, but patients systemically affected at AAP diagnosis are 
at increased risk of developing pseudocysts, acute or persistent dia-
betes mellitus, and chronic/relapsing pancreatitis175,178. Octreotide 
has been tested in few patients, but the benefit thereof remains to 
be determined179,180.
The risk of a second AAP after re-exposing patients with AAP to 
asparaginase is almost 50% and does not seem to be significantly 
lower if the first AAP episode was classified as mild170,174,175.
Risk factors for AAP are few, although the incidence is associated 
with older age. Polymorphisms in PRSS1, SPINK1, ASNS, ULK2, 
RGS6, and CPA2 genes have been associated either with pediat-
ric pancreatitis in general or with AAP162,174,181,182, although these 
associations await validation.
Hyperlipidemia
Elevated triglycerides and cholesterol occur frequently during 
ALL therapy and are associated with corticosteroid and aspara-
ginase therapy7,78,83,183. However, patients are generally com-
pletely unaffected, even when levels are 40 to 50 times the UNL, 
the association with specific toxicities is very uncertain, and 
accordingly neither routine measurements nor interventions are 
recommended7.
The hypertriglyceridemia is likely related to an increase in the 
endogenous hepatic synthesis of very low-density lipoprotein com-
bined with a decreased activity in lipoprotein lipase, an enzyme 
involved in the removal of triglyceride-rich lipoproteins from the 
plasma184.
The most common preventive measures in cases of hypertriglyc-
eridemia are dietary restrictions (very limited effect), fibrates, 
insulin infusions, heparin infusions, and in extreme cases plas-
mapheresis, but there are no data to support that any of these 
interventions reduces the risk of hypertriglyceridemia-associ-
ated toxicities83,185–189. In adults with non-malignant disorders, 
hypertriglyceridemia (above 10 times the UNL) has been asso-
ciated with an increased risk of acute pancreatitis185,188,190, but so 
far this has not been replicated in children with ALL191. A few 
studies have indicated associations with development of ON and 
thrombosis78,83,95,158,188,192, but no randomized studies have 
explored whether lipid-lowering interventions prevent these 
complications.
Host genome variant associations
As mentioned above, multiple variants in germline DNA have 
been associated with the pharmacology of anti-leukemic agents, 
including the risk of toxicities6,68,193, but their individual haz-
ard ratios are generally low (<2.0), the variants are rare or lack 
validation in independent studies, and treatment alterations 
according to such variants so far have not been implemented in 
childhood ALL therapy. The main reasons for our current inabil-
ity to identify clinically actionable germline variants associated 
with specific toxicities are lack of sufficient study power (since 
each toxicity is rare and few trial groups are investigating genotype 
variation), incomplete toxicity capture, lack of detailed phenotyp-
ing (for example, lumping all subtypes and grades of a toxicity), 
and exploration of single-nucleotide polymorphisms rather than 
biological pathways. To address these limitations, the PTWG is 
now collecting phenotypes of several acute toxicities (pancreati-
tis, ON, and CNS toxicities) in hundreds of patients for each of 
these toxicities to associate detailed phenotypes with germline 
DNA variants175.
Leukemia predisposition syndromes
Recent research has identified several germline mutations in 
genes that play a critical role in hematopoiesis and lymphoid devel-
opment and that are also frequently somatically mutated in ALL, 
such as PAX5194,195, ETV6196,197, RUNX11198, and IKZF1199, which 
align with the findings of high subtype concordance in famil-
ial cases of ALL195,197,200,201. This indicates that pure familial ALL 
syndromes may constitute a substantial part of ALL etiology and 
that more such syndromes are expected to emerge in parallel with 
a growing number of patients being germline-sequenced and with 
a deeper understanding of the impact of coding and non-coding 
DNA interactions196. However, the impact of such germline DNA 
mutations on toxicities, not least those involving the bone marrow 
and immune system, remains to be determined. The risk of second 
malignant neoplasms may also be increased when childhood ALL 
arises due to a predisposition syndrome. Unusual acute toxicities 
and second malignant neoplasms therefore should lead to clinical 
suspicion of an underlying syndrome202.
Down syndrome is the most frequent known germline mutation 
predisposing to ALL and is associated with enhanced gastrointes-
tinal toxicity203. However, reducing treatment intensity may also 
increase the risk of relapse204 and should be considered only in case 
of excessive toxicity in the 10 to 15% of Down syndrome-ALL 
patients who harbor high hyperdiploidy or an ETV6-RUNX1 trans-
location, since these subsets have a superior cure rate205.
Several other ALL-predisposing syndromes such as Li-Fraumeni, 
ataxia telangiectasia, Nijmegen breakage, biallelic mismatch 
repair, and Fanconi anemia can also exhibit syndrome-related 
toxicities when exposed to DNA-damaging anti-cancer agents or 
radiotherapy206–209. In such cases, a reduction of DNA-damaging 
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drug doses must be considered on an individual basis, and at 
least for ataxia telangiectasia and Nijmegen breakage dose reduc-
tion may not be associated with an increased risk of relapse210. In 
contrast, thiopurine-based maintenance therapy may be less 
efficient in patients with biallelic mismatch repair deficiency, 
since this pathway is critical for thiopurine cytotoxicity211.
Future research
The low frequency and poor definitions of most of the listed 
organ toxicities have hampered their in-depth exploration, includ-
ing the impact of specific drug dosing regimens, and identifica-
tion of clear risk factors for certain phenotypic subsets. The recent 
PTWG consensus definitions of 14 of these toxicities have pro-
vided a platform for international collaboration on these issues7. 
The results from the first of such explorations demonstrate its 
feasibility175 and may allow exploration of the association 
between risk factors, including host DNA variants, in well-defined 
phenotypic subsets and provide evidence-based guidelines for 
treatment adaptation. Furthermore, the association of these acute 
toxicities with the risk of long-term organ toxicities (for example, 
dementia, diabetes, arthrosis, and chronic pancreatitis) remains to 
be mapped. Currently, event-free survival measures encompass 
death during induction, resistance to first-line therapy, relapse 
of leukemia, non-leukemic death during clinical remission, and 
development of a second cancer. However, many patients with 
a late relapse or a second cancer have a fair chance of cure212,213, 
whereas chronic toxicities are generally irreversible and challenge 
patients’ ability to live a normal adult life214. This calls for new 
endpoint measures that include both survival and quality of life, 
which will require common strategies for toxicity capture and 
registration, and international collaboration to identify host 
genome variants and exposures (for example, anti-leukemic treat-
ment, co-medication, and diet) associated with the risk of specific 
toxicities, but it also demands the development of a joint endpoint 
scoring system that encompasses OS as well as severe toxicities, 
both acute and long-term.
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